Share on StockTwits

Gilead Sciences (NASDAQ:GILD) EVP Paul Rutherford Carter sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $106.16, for a total transaction of $1,061,600.00. Following the sale, the executive vice president now directly owns 32,244 shares of the company’s stock, valued at approximately $3,423,023. The sale was disclosed in a legal filing with the SEC, which is available at this link.

GILD has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday, August 22nd. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $105.55.

Gilead Sciences (NASDAQ:GILD) traded up 0.09% during mid-day trading on Thursday, hitting $107.51. The stock had a trading volume of 10,287,398 shares. Gilead Sciences has a 52 week low of $58.50 and a 52 week high of $108.77. The stock has a 50-day moving average of $93.83 and a 200-day moving average of $82.64. The company has a market cap of $162.5 billion and a price-to-earnings ratio of 24.33. Gilead Sciences also was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 23,938 put options on the stock. This represents an increase of 116% compared to the average volume of 11,107 put options.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $8.00 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.